Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Genasense: Phase I/II data; Phase III

Of 22 evaluable patients with hormone refractory prostate cancer in a 26-patient dose escalation Phase

Read the full 159 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE